← Leaderboards
Gail E Sonenshein
Boston University Medical Campus
$16,606,360
Attributed
$16,606,360
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$28,049,005 · 13
By mechanism
P01$14,422,557 · 4
R01$8,513,111 · 4
R44$4,002,084 · 2
R41$416,490 · 1
R21$394,763 · 1
R43$300,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Jan Krzysztof Blusztajn$11,412,004
- Douglas V Faller$14,088,389
- Barbara A Gilchrest$2,915,124
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGrowthCellsTranscription FactorMouse ModelMalignant Breast NeoplasmCell LineIn VivoPhenotypeIn VitroMalignant NeoplasmsOncogenesMediatingTissuesClinicInhibitor/AntagonistLeadFundingBreast Cancer CellGene ExpressionWomanPre-ClinicalPathway InteractionsCessation Of Life
Grant awards (68)
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$1,000,000
R44 · FY2023 · CA · contact PI
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$1,000,000
R44 · FY2022 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$1,000,000
R44 · FY2019 · CA · contact PI
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$300,000
R43 · FY2019 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$2,084
R44 · FY2019 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$1,000,000
R44 · FY2018 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$3,000
R41 · FY2018 · CA · contact PI
ADAM8 Is a Novel Target for Treatment of Triple-Negative Breast Cancer$179,438
R21 · FY2017 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$50,000
R41 · FY2017 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$300,000
R41 · FY2016 · CA · contact PI
ADAM8 Is a Novel Target for Treatment of Triple-Negative Breast Cancer$215,325
R21 · FY2016 · CA · contact PI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$63,490
R41 · FY2016 · CA · contact PI
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor$484,359
R01 · FY2014 · CA · contact PI
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor$469,312
R01 · FY2013 · CA · contact PI
Signaling Pathways in Stages of Tumorigenesis$1,080,598
P01 · FY2012 · ES · contact PI
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor$505,629
R01 · FY2012 · CA · contact PI
Roles of NF-kB/Rel in the pathogenesis of breast cancer$331,971
R01 · FY2012 · CA · contact PI
CORE A: Administrative Core$250,013
P01 · FY2012 · ES · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$127,137
P01 · FY2012 · ES · contact PI
Signaling Pathways in Stages of Tumorigenesis$1,076,516
P01 · FY2011 · ES · contact PI
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor$504,724
R01 · FY2011 · CA · contact PI
Roles of NF-kB/Rel in the pathogenesis of breast cancer$337,550
R01 · FY2011 · CA · contact PI
CORE A: Administrative Core$240,544
P01 · FY2011 · ES · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$135,383
P01 · FY2011 · ES · contact PI
Signaling Pathways in Stages of Tumorigenesis$1,136,893
P01 · FY2010 · ES · contact PI
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor$527,955
R01 · FY2010 · CA · contact PI
Roles of NF-kB/Rel in the pathogenesis of breast cancer$352,574
R01 · FY2010 · CA · contact PI
CORE A: Administrative Core$225,320
P01 · FY2010 · ES · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$140,178
P01 · FY2010 · ES · contact PI
Signaling Pathways in Stages of Tumorigenesis$629,660
P01 · FY2009 · ES · contact PI
Signaling Pathways in Stages of Tumorigenesis$432,306
P01 · FY2009 · ES · contact PI
Roles of NF-kB/Rel in the pathogenesis of breast cancer$337,188
R01 · FY2009 · CA · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$167,648
P01 · FY2009 · ES · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$162,768
P01 · FY2009 · ES · contact PI
CORE A: Administrative Core$69,922
P01 · FY2009 · ES · contact PI
CORE A: Administrative Core$67,886
P01 · FY2009 · ES · contact PI
Signaling Pathways in Stages of Tumorigenesis$1,043,958
P01 · FY2008 · ES · contact PI
Roles of NF-kB/Rel in the pathogenesis of breast cancer$337,188
R01 · FY2008 · CA · contact PI
LYSYL OXIDASE INHIBITION OF RAS-MEDIATED TRANSFORMATION$275,637
R01 · FY2008 · CA · contact PI
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis$158,026
P01 · FY2008 · ES · contact PI
CORE A: Administrative Core$65,908
P01 · FY2008 · ES · contact PI
LYSYL OXIDASE INHIBITION OF RAS-MEDIATED TRANSFORMATION$401,255
R01 · FY2007 · CA · contact PI
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS$287,887
R01 · FY2007 · CA · contact PI
LYSYL OXIDASE INHIBITION OF RAS-MEDIATED TRANSFORMATION$408,564
R01 · FY2006 · CA · contact PI
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS$296,485
R01 · FY2006 · CA · contact PI
Signaling Pathways in Stage of Mammary Tumorigenesis$1,280,729
P01 · FY2005 · ES
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS$303,620
R01 · FY2005 · CA
LYSYL OXIDASE INHIBITION OF RAS-MEDIATED TRANSFORMATION$290,700
R01 · FY2005 · CA
Signaling Pathways in Stage of Mammary Tumorigenesis$1,243,428
P01 · FY2004 · ES
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS$303,620
R01 · FY2004 · CA
LYSYL OXIDASE INHIBITION OF RAS-MEDIATED TRANSFORMATION$290,700
R01 · FY2004 · CA
Signaling Pathways in Stage of Mammary Tumorigenesis$1,207,211
P01 · FY2003 · ES
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS$303,620
R01 · FY2003 · CA
Coordinated Control of Vascular SMC Growth &Fibrogeneni$243,397
P01 · FY2003 · HL
NFKB/REL AND THE PATHOGENESIS OF BREAST CANCER$42,285
R01 · FY2003 · CA
Signaling Pathways in Stage of Mammary Tumorigenesis$1,172,048
P01 · FY2002 · ES
B-MYB REGULATION OF MATRIX GENE EXPRESSION$308,594
P01 · FY2002 · HL
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE$27,750
R01 · FY2002 · CA
ROLE OF NFKB/REL IN MAMMARY CARCINOGENESIS$0
P01 · FY2002 · ES
Signaling Pathways in Stage of Mammary Tumorigenesis$1,139,298
P01 · FY2001 · ES
B-MYB REGULATION OF MATRIX GENE EXPRESSION$308,594
P01 · FY2001 · HL
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE$285,360
R01 · FY2001 · CA
NFKB/REL AND THE PATHOGENESIS OF BREAST CANCER$255,705
R01 · FY2001 · CA
NFKB/REL AND THE PATHOGENESIS OF BREAST CANCER$22,984
R01 · FY2001 · CA
ROLE OF NFKB/REL IN MAMMARY CARCINOGENESIS$0
P01 · FY2001 · ES
B-MYB REGULATION OF MATRIX GENE EXPRESSION$308,594
P01 · FY2000 · HL
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE$278,988
R01 · FY2000 · CA
NFKB/REL AND THE PATHOGENESIS OF BREAST CANCER$249,501
R01 · FY2000 · CA